This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ballester, M. Articles by Estorch, M. Search for Related Content PubMed PubMed Citation Articles by Ballester, M. Articles by Estorch, M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Transplantation

Circulation, Vol 85, 61-68, Copyright © 1992 by American Heart Association

ARTICLES

Early postoperative reduction of monoclonal antimyosin antibody uptake is associated with absent rejection-related complications after heart transplantation

M Ballester, D Obrador, I Carrio, C Moya, JM Auge, R Bordes, V Marti, I Bosch, L Berna-Roqueta and M Estorch
Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

BACKGROUND. Detection and treatment for rejection after transplantation are based on the identification of myocyte damage upon endomyocardial biopsy. Noninvasive detection of such damage is possible with 111In- labeled monoclonal antimyosin antibodies (MAA). Although the presence and degree of MAA uptake parallels the rejection activity detected by biopsy, the relation between the degree of uptake and the occurrence of severe rejection-related complications has not been previously assessed. METHODS AND RESULTS. Two hundred forty-seven MAA studies were performed coinciding with biopsies in 52 patients 1-71 months after transplantation. A heart-to-lung ratio (HLR) was used as a measure of relative MAA uptake, with an HLR of 1.55 discriminating normal from abnormal studies. Of the 247 antimyosin studies, 149 coincided with absent, 38 with mild, and 60 with moderate rejection at biopsy. HLR was 1.68 +/- 0.27, 1.79 +/- 0.22, and 1.91 +/- 0.33 in the three biopsy groups, respectively (p less than 0.0001). Two hundred thirty-eight of 247 antimyosin studies coexisted with absent rejection-related complications; in nine of 247 patients, such complications were detected (five congestive heart failure episodes due to rejection and four episodes of vascular occlusion, which resulted in five deaths), and mean HLR was 1.74 +/- 0.3 and 2.1 +/- 0.16 in the two groups, respectively (p less than 0.0001). No complications were noted in 193 studies of patients with HLR of less than 2.00, whereas in nine of 45 with HRL of 2.00 or greater, complications occurred (p less than 0.0001). None of the 23 patients prospectively followed since surgery who had a gradual decrease in MAA uptake during the first 3 months showed rejection-related complications, whereas persistent uptake was associated with complications in five of nine patients (p less than 0.001). CONCLUSIONS. No rejection-related complications are seen coinciding with HLR of less than 2.00, whereas patients who have complications have an HLR of more than 2.00. The early 3-month pattern of decreasing MAA uptake is associated with a clinical course free of rejection-related complications, whereas a persistent pattern is a signal of the possibility of such complications.

This article has been cited by other articles:

				M. E. R. Martin, J. L. Moya-Mur, M. Casanova, A. Crespo-Diez, E. Asin-Cardiel, J. M. Castro-Beiras, L. Diez-Jimenez, M. Ballester, I. Carrio, and J. Narula Role of Noninvasive Antimyosin Imaging in Infants and Children with Clinically Suspected Myocarditis J. Nucl. Med., March 1, 2004; 45(3): 429 - 437. [Abstract] [Full Text]

				A. I. McGhie, B. Radovancevic, P. Capek, W. H. Moore, L. Kasi, L. Lamki, F. J. Clubb Jr, O. H. Frazier, and J. T. Willerson Major Histocompatibility Complex Class II Antigen Expression in Rejecting Cardiac Allografts : Detection Using In Vivo Imaging With Radiolabeled Monoclonal Antibody Circulation, September 2, 1997; 96(5): 1605 - 1611. [Abstract] [Full Text]

				V. Marti, M. Ballester, C. Udina, I. Carrio, E. Alvarez, D. Obrador, and G. Pons-Llado Evaluation of Myocardial Cell Damage by In-111-Monoclonal Antimyosin Antibodies in Patients Under Chronic Tricyclic Antidepressant Drug Treatment Circulation, March 15, 1995; 91(6): 1619 - 1623. [Abstract] [Full Text]

				J. Bergler-Klein, H. Sochor, G. Stanek, S. Globits, R. Ullrich, and D. Glogar Indium 111--Monoclonal Antimyosin Antibody and Magnetic Resonance Imaging in the Diagnosis of Acute Lyme Myopericarditis Arch Intern Med, December 13, 1993; 153(23): 2696 - 2700. [Abstract] [PDF]